Oramed is a pioneering pharmaceutical company primarily focused on developing proprietary oral drug delivery technology based on over two decades of research at Hadassah University Hospital’s Diabetes Unit in Jerusalem. The Company’s leading candidate ORMD 0801, an oral insulin capsule, promises to provide revolutionary advancement in the treatment of diabetes, having already demonstrated a very favorable safety profile in testing.
With targeted blood glucose results meeting expectations it seems clear that ORMP has its hands on a proprietary gold mine. The global market for type 2 diabetes is quite large and this breakthrough represents a major boost to the standard of living for most patients.
Oramed intends to exploit this powerful technology as a platform for other drug delivery, from vaccines to a variety of medications which are currently only available in injected form. Even with the advent of modern, relatively passive injection systems, the appeal of an oral delivery method for its ease of use and overall safety is incredibly high.
Let us hear your thoughts: Oramed Pharmaceuticals, Inc. Message Board